This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Tung-Ping Su, MD; Anil K. Malhotra, MD; Kayleen Hadd, RN, MSN; Alan Breier, MD; David Pickar, MD
Experimental Therapeutics Branch National Institute of Mental Health Bldg 10, Room 4N212 10 Center Dr MSC 1380 Bethesda, MD 20892-1380

Arch Gen Psychiatry. 1997;54(10):972-973.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The atypical antipsychotic agents, clozapine and risperidone, have a similar pharmacological profile of D₂ dopamine receptor affinity, ₂, and serotonin² antagonism.¹ Despite this similarity, the clinical profile of these 2 drugs are quite different. For instance, risperidone produces dose-dependent extrapyramidal side effects, whereas clozapine does not.² Moreover, there may be differences in the antipsychotic efficacy of these 2 drugs n treatment-resistant patients. One possibility for this difference in clinical profile is that these drugs produce different levels of D₂ receptor occupancy. Previous estimates of D₂ receptor occupancy of these atypical agents have examined different individuals and do not account for interindividual variation.^{3, 4} We are, therefore, conducting a double-blind, randomized, crossover sodium iodide I123-benzamide—single photon emission computed tomographic study with schizophrenic patients treated with fixed doses of clozapine and risperidone to investigate the degree of D₂ receptor occupancy by these drugs.

To date, we . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?